Market Size of Canine Atopic Dermatitis Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.46 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Canine Atopic Dermatitis Market Analysis
The canine atopic dermatitis market is expected to witness a CAGR of 8.46% over the forecast period.
The COVID-19 pandemic led to disruption in not only the research and development activities of veterinary diseases but also disrupted the logistics supply of various essential pharmaceutical products for pets. For instance, according to an article published by Frontiers in May 2022, a study was conducted in the United Kingdom which showed that a dog's chronic illness diagnosis reduced the odds of seeking care during the pandemic, it was reportedly due to difficulties in accessing care for non-urgent issues, and lack of access to a veterinarian was a major factor behind it. Thus, the COVID-19 pandemic had a significant impact on the studied market. However, with the declining COVID-19 cases and ease of restrictions, the studied market is expected to regain its full potential over the years.
The major factors that are driving the growth of the market are the increasing pollution due to allergens, and the increase in dog adoption.
The rising adoption of dogs is a major factor driving the market growth. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report, 10,300,000 dogs were reported in Germany in 2021. As per the same source, the percentage of German households owning at least one dog was 19% in 2021. This shows that the adoption of dogs was high in the country which is expected to drive market growth.
Similarly, as per the Pet Food Manufacturer's Association (PFMA), pet Population 2022 data published in 2022, it was estimated that 34.9 million pets will be there in the United Kingdom in 2022, among which 13 million will be dogs. Thus, the increasing adoption of dogs is expected to increase the demand for atopic dermatitis medications. This is further anticipated to drive market growth.
Additionally, the increasing indoor allergen pollution is also increasing the prevalence of atopic dermatitis in dogs, thus driving market growth. For instance, according to an article published by Wiley Online Library in September 2022, a study was conducted which showed that exposure to indoor air pollution increased the development of atopic dermatitis in dogs.
Moreover, the developments by key market players are expected to increase market growth. For instance, in November 2021, Vimian Group entered a partnership with Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals including dogs.
Thus, the aforementioned factors such as the rising dog adoption and the increasing developments by key market players are expected to boost the market growth. However, the usage of off-label drugs is expected to hinder market growth.
Canine Atopic Dermatitis Industry Segmentation
As per the scope of the report, canine atopic dermatitis is the chronic inflammation on the skin of dogs, often caused by allergens such as pollens, fleas, or other insect bites, and food ingredients. The canine atopic dermatitis market is segmented by treatment type (glucocorticoids, immunosuppressants, monoclonal antibody, and other treatment types), route of administration (topical, oral, and injectable), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value in USD million for the abovementioned segments.
| By Treatment Type | |
| Glucocorticoids | |
| Immunosuppressants | |
| Monoclonal Antibody | |
| Other Treatment Types |
| By Route of Administration | |
| Topical | |
| Oral | |
| Injectable |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Canine Atopic Dermatitis Market Size Summary
The canine atopic dermatitis market is poised for significant growth, driven by factors such as increasing dog adoption and rising indoor allergen pollution. The market experienced disruptions due to the COVID-19 pandemic, which affected research and development activities and logistics for essential veterinary pharmaceuticals. However, as restrictions ease, the market is expected to recover and expand. The growing awareness of biotherapeutics and the development of novel treatments, such as monoclonal antibodies, are further propelling market growth. Key players in the industry are actively engaging in partnerships and product innovations to enhance their market presence.
North America is anticipated to be a key region for market expansion, supported by high dog ownership rates and substantial investments in research and development. The United States, in particular, is expected to hold a significant market share due to its large dog population and high spending on animal health. The competitive landscape is characterized by the presence of major players like Zoetis, Elanco, and Virbac, who are employing strategies such as mergers, acquisitions, and new product launches to strengthen their market position. Overall, the combination of rising dog adoption, increasing prevalence of atopic dermatitis, and ongoing advancements in treatment options is expected to drive the market forward.
Canine Atopic Dermatitis Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Pollution Related to Allergens
-
1.2.2 Increasing Dog Ownership
-
-
1.3 Market Restraints
-
1.3.1 Usage of Off-label Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Treatment Type
-
2.1.1 Glucocorticoids
-
2.1.2 Immunosuppressants
-
2.1.3 Monoclonal Antibody
-
2.1.4 Other Treatment Types
-
-
2.2 By Route of Administration
-
2.2.1 Topical
-
2.2.2 Oral
-
2.2.3 Injectable
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Canine Atopic Dermatitis Market Size FAQs
What is the current Canine Atopic Dermatitis Market size?
The Canine Atopic Dermatitis Market is projected to register a CAGR of 8.46% during the forecast period (2024-2029)
Who are the key players in Canine Atopic Dermatitis Market?
Zoetis, Virbac, Toray Industries Inc., Elanco and Dechra Pharmaceuticals PLC are the major companies operating in the Canine Atopic Dermatitis Market.
